Home Others Other chemical 2-Methylenebutyrolactone

research use only

2-Methylenebutyrolactone

Cat.No.S5148

2-Methylenebutyrolactone (Tulipalin A, MBL, α-methylene-γ-butyrolactone), also known as α-methylene-γ-butyrolactone (MBL) (Tulipalin A), belongs to the class of sesquiterpene lactone family and is considered as cyclic analog of most common vinyl monomer methyl methacrylate (MMA).
2-Methylenebutyrolactone Chemical Structure

Chemical Structure

Molecular Weight: 98.10

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 98.10 Formula

C5H6O2

 Storage (From the date of receipt) 2 years  -20°C  liquid
CAS No. 547-65-9 Download SDF Storage of Stock Solutions

Solubility

In vitro
Batch:

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro
After exposure of Jurkat T cells to 2-Methylenebutyrolactone (Tulipalin A , TUPA) for 72 h, a dose dependent toxicity is detected. Concentrations higher than 20 μM lead to a significant reduction of viable cells. Compared to vehicle-treated control cells, concentrations of 47.6 and 26.8 μM decrease the cell viability significantly by 50% (IC50) and 10% (IC10), respectively. In contrast, THP-1 cells are less sensitive toward TUPA. Concentrations >41 μM lead to a significant reduction of viable cells. IC10 is calculated with 50 μM, whereas a concentration of 83 μM is necessary to decrease the cell viability to 50% (IC50). In Jurkat T cells, four proteins responsible for the de novo purine synthesis, namely phosphoribosylformylglycinamidine synthase (PFAS), GMP synthase (GMPS), and ribosephosphate pyrophosphokinases 1 and 2 (PRPS1/2) are increased through TUPA treatment. Glutamine is also increased after TUPA treatment. In addition to the proteins belonging to the purine synthesis pathway, the abundances of proteins for DNA synthesis and repair (XRCC5, XRCC6, MCM3, MCM6, MCM7, TRA1) are also increased/induced during the treatment. While in THP-1 cells, no indication for higher purine synthesis induced by TUPA in subtoxic concentrations is discovered. TUPA induces the expression of proteins in Jurkat T cells responsible for cell stress, drug response, and protein folding: HYOU1, PDIA3, and DNAJB11. Additionally, the treatment with TUPA leads to the induction of three heat shock proteins (HSP90AA1, HSP90AB1, and HSP90B1) and three proteins belonging to the TRiC complex (CCT3,6,8) that are also responsible for proper protein folding. Treatment with TUPA leads to the induction of ROS that have adverse effects on Jurkat T cells and evokes slight cell stress responses in THP-1 cells. TUPA has influence on proteins in Jurkat T cells that contribute to different immune-specific, especially immunostimulating, reactions as allergic contact dermatitis. In THP-1 cells, no proteins regarding immune-specific reactions are up- or downregulated due to TUPA treatment[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05850871 Recruiting
Carbapenem-Resistant Enterobacteriaceae Infection
Qianfoshan Hospital
 January 6 2023 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.